INCY - Incyte Corporation
| Previous close | 93.80 |
| Open | 93.17 |
| Bid | 95.05 x 900 |
| Ask | 95.27 x 2200 |
| Day's range | 90.17 - 96.18 |
| 52-week range | 62.48 - 104.81 |
| Volume | 302,609 |
| Avg. volume | 2,067,539 |
| Market cap | 20.781B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | 51.10 |
| EPS (TTM) | 1.87 |
| Earnings date | 28 Jul 2020 - 03 Aug 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 102.07 |
- Zacks
Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Incyte to Present at Upcoming Investor Conferences
Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:
- Business Wire
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
- Zacks
Incyte, MorphoSys Application for Lymphoma Drug Validated
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
- Business Wire
Incyte to Present at Upcoming Investor Conference
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference (held virtually) on Tuesday, June 9, 2020 at 8:00 a.m. ET.
- Business Wire
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab
- Zacks
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
- Business Wire
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
- Yahoo Finance
Coronavirus Vaccine Progress Accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
- Motley Fool
MorphoSys AG (MOR) Q1 2020 Earnings Call Transcript
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.
- Simply Wall St.
Incyte Corporation (NASDAQ:INCY) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
The quarterly results for Incyte Corporation (NASDAQ:INCY) were released last week, making it a good time to revisit...
- Business Wire
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
- Motley Fool
Incyte Corp (INCY) Q1 2020 Earnings Call Transcript
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for 2020 guidance, the commercialization of our products, and our development plans and expectations for the compounds in our pipeline, as well as the development plans of our collaboration partners. With regards to clinical development, as of today, while our late-stage programs remain broadly on track, we anticipate that short-term effects may continue to emerge across different aspects of our global clinical trial programs, including new patient recruitment.
- Motley Fool
Why Incyte's Q1 Loss Isn't As Bad As It Looks
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
- Zacks
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
- Motley Fool
Incyte Reports a Q1 Loss Due to MorphoSys Deal
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
- Zacks
Incyte (INCY) Reports Q1 Loss, Tops Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
- Yahoo Finance
Disney, Beyond Meat earnings, ISM non-manufacturing: What to know in markets Tuesday
The U.S. services sector data and earnings from media giant Disney and plant-based protein maker Beyond Meat will be in focus on a busy Tuesday.
- Motley Fool
Is Incyte Stock a Buy?
Incyte (NASDAQ: INCY) has performed well since the beginning of the year. Year to date, the biotech company's shares are up by 19%, while the S&P 500 is down by 11% over the same period. The company is currently trading at 44.2 times future earnings.
- Business Wire
Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada
Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada
- Business Wire
Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease
Incyte Announces Pivotal REACH2 Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi) versus BAT Patients with Acute GVHD
